Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B CORAL TRIAL OF HADUVIO FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IPF CLOSED $115 MILLION UNDERWRITTEN OFFERING WITH EXPECTED CASH RUNWAY INTO 2029 MANAGEMENT TO HOST A CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET NEW HAVEN, CONN.

TREVI THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

CONFERENCE CALL AND WEBCAST TO BE HELD AT 4:30 P.M. ET  NEW HAVEN, CONN.

TREVI THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE ON AUGUST 7, 2025

NEW HAVEN, CONN. , JULY 29, 2025 /PRNEWSWIRE/ --TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF), NON-IPF INTERSTITIAL LUNG DISEASE (NON-IPF ILD), AND REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING CONFERENCES IN AUGUST.

TREVI THERAPEUTICS TO PARTICIPATE IN UPCOMING AUGUST CONFERENCES

NEW HAVEN, CONN. , JULY 1, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT JENNIFER GOOD, PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND LISA DELFINI, CHIEF FINANCIAL OFFICER, WILL BE ATTENDING LEERINK PARTNERS THERAPEUTICS FORUM: I&I AND METABOLISM, HELD FROM JULY 8-9 IN BOSTON, MASSACHUSETTS.

TREVI THERAPEUTICS TO ATTEND LEERINK PARTNERS THERAPEUTICS FORUM: I&I AND METABOLISM

NEW HAVEN, CONN. , JUNE 5, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO(ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 20,010,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.75 PER SHARE, WHICH INCLUDES 2,610,000 ADDITIONAL SHARES ISSUED UPON THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK IN THE PUBLIC OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS.

TREVI THERAPEUTICS ANNOUNCES CLOSING OF $115 MILLION UNDERWRITTEN OFFERING AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES

NEW HAVEN, CONN. , JUNE 3, 2025 /PRNEWSWIRE/ --TREVI THERAPEUTICS, INC.(NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO(ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 17,400,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $5.75 PER SHARE, FOR TOTAL PROCEEDS OF $100 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND EXPENSES PAYABLE BY TREVI.

TREVI THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

NEW HAVEN, CONN. , JUNE 2, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100,000,000 OF SHARES OF ITS COMMON STOCK.

TREVI THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

HADUVIO MET THE PRIMARY ENDPOINT WITH STATISTICALLY-SIGNIFICANT REDUCTIONS IN 24-HOUR COUGH FREQUENCY ACROSS ALL DOSE GROUPS (108 AND 54 MG BID P

TREVI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE 2B CORAL TRIAL OF HADUVIO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS CHRONIC COUGH

CONFERENCE CALL AND WEBCAST TO BE HELD AT 8:30 A.M. ET  NEW HAVEN, CONN.

TREVI THERAPEUTICS TO HOST CONFERENCE CALL AND WEBCAST ON JUNE 2ND TO SHARE TOPLINE RESULTS FROM THE PHASE 2B CORAL TRIAL OF HADUVIO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS CHRONIC COUGH

NEW HAVEN, CONN. , MAY 29, 2025 /PRNEWSWIRE/ -- TREVI THERAPEUTICS, INC. (NASDAQ: TRVI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THE INVESTIGATIONAL THERAPY HADUVIO (ORAL NALBUPHINE ER) FOR THE TREATMENT OF CHRONIC COUGH IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND IN PATIENTS WITH REFRACTORY CHRONIC COUGH (RCC), TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL BE PARTICIPATING IN THE FOLLOWING CONFERENCES IN JUNE.

Trevi Therapeutics, Inc.

TRVI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Trevi Therapeutics, Inc.

TRVI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TRVI